Sands Capital Life Sciences Pulse Fund II, L.P.
SEC insider (Form 3/4/5 filer). CIK 0001875620. 10% Owner at Inhibikase Therapeutics, Inc. (IKT). 1 reported Form 4/5 transaction since Sep 2024; latest on Nov 21, 2025. Located in ARLINGTON, VA.
Companies Sands Capital Life Sciences Pulse Fund II, L.P. has filed insider reports for
- Inhibikase Therapeutics, Inc. (IKT): 10% Owner
Sands Capital Life Sciences Pulse Fund II, L.P.
CIK: 0001875620
Transaction Breakdown
Open Market Buys (P)1 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
IKT
Inhibikase Therapeutics, Inc.
10% Owner